On Oct. 29, 2020, Humanigen announced that the first patient had been dosed at the Emory University School of Medicine in Atlanta, Georgia as part of the in the ACTIV-5 ﾓBig Effect Trialﾔ (ACTIV-5/BET) evaluating lenzilumab with remdesivir, compared to placebo and remdesivir, in patients hospitalized with COVID-19.

Lenzilumab is the Companyﾒs lead product candidate and proprietary Humaneeredﾮanti-human granulocyte macrophage-colony stimulating factor monoclonal antibody designed to optimize antibody properties.